Related references
Note: Only part of the references are listed.Whole Exome Sequencing of Relapsed/Refractory Patients Expands the Repertoire of Somatic Mutations in Diffuse Large B-Cell Lymphoma
Sylvain Mareschal et al.
GENES CHROMOSOMES & CANCER (2016)
Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia
Zachary A. Hing et al.
BLOOD (2015)
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing
David M. Kurtz et al.
BLOOD (2015)
High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates
Irina Bonzheim et al.
BLOOD (2015)
MYD88 Expression and L265P Mutation in Mature B-Cell Non-Hodgkin Lymphomas
Vildan Caner et al.
GENETIC TESTING AND MOLECULAR BIOMARKERS (2015)
Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis
Elodie Bohers et al.
HAEMATOLOGICA (2015)
Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer
David Sefrioui et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Large B-cell lymphoma: is the future written in the blood?
Sarah-Jane Dawson et al.
LANCET ONCOLOGY (2015)
Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study
Mark Roschewski et al.
LANCET ONCOLOGY (2015)
Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations
So Yamada et al.
LEUKEMIA & LYMPHOMA (2015)
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson et al.
NATURE MEDICINE (2015)
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer
Gaia Schiavon et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: Implications for targeted EZH2 inhibitor therapy?
Sydney Dubois et al.
ONCOTARGET (2015)
Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis
Elodie Bohers et al.
HAEMATOLOGICA (2015)
Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy
Pierre Laurent-Puig et al.
CLINICAL CANCER RESEARCH (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas
Alicia A. Tone et al.
BMC CANCER (2014)
Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer
Julia A. Beaver et al.
CLINICAL CANCER RESEARCH (2014)
Targetable Activating Mutations are Very Frequent in GCB and ABC Diffuse Large B-Cell Lymphoma
Elodie Bohers et al.
GENES CHROMOSOMES & CANCER (2014)
Liquid Biopsies: Genotyping Circulating Tumor DNA
Luis A. Diaz et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
Sarah K. Knutson et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Multiplex Picodroplet Digital PCR to Detect KRAS Mutations in Circulating DNA from the Plasma of Colorectal Cancer Patients
Valerie Taly et al.
CLINICAL CHEMISTRY (2013)
Absolute quantification by droplet digital PCR versus analog real-time PCR
Christopher M. Hindson et al.
NATURE METHODS (2013)
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
H. Tilly et al.
ANNALS OF ONCOLOGY (2012)
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe et al.
NATURE (2012)
Digital PCR hits its stride
Monya Baker
NATURE METHODS (2012)
Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay
Hyun-Gyung Goh et al.
LEUKEMIA & LYMPHOMA (2011)
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo et al.
NATURE (2011)
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Jonathan W. Friedberg
HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM (2011)
If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma
Patrizia Mancuso et al.
BMC CANCER (2010)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
Mara Compagno et al.
NATURE (2009)
Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer
K Jung et al.
CANCER LETTERS (2004)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)
Quantification of free circulating DNA as a diagnostic marker in lung cancer
G Sozzi et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Isotype-switched immunoglobulin genes with a high load of somatic hypermutation and lack of ongoing mutational activity are prevalent in mediastinal B-cell lymphoma
F Leithäuser et al.
BLOOD (2001)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
Share Paper
